Who makes Ropivacaine 0,75%?

Ropivacaine 0,75% is developed by North Karelia Central Hospital.

What development phase is Ropivacaine 0,75% in?

Ropivacaine 0,75% is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Ropivacaine 0,75%

North Karelia Central Hospital · FDA-approved active Small molecule Quality 0/100

Ropivacaine 0.75%, marketed by North Karelia Central Hospital, is an established anesthetic with a key composition patent expiring in 2028. The drug's primary strength lies in its well-documented efficacy and safety profile, positioning it as a reliable option in the anesthetic market. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Ropivacaine 0,75%
Also known as	Naropin 0,75%
Sponsor	North Karelia Central Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ropivacaine 0,75% CI brief — competitive landscape report
Ropivacaine 0,75% updates RSS · CI watch RSS
North Karelia Central Hospital portfolio CI